Advanced Enzyme Technologies Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Advanced Enzyme Technologies Ltd trades at ₹293, in a downtrend and 3 weeks into that stage. That is −8.1% against its own 200-day average. It sits at 25% of a 52-week range of ₹266 to ₹377. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (12 weeks and counting).

Today the stock is in a downtrend — week 3 of stage 4, confirmed. At ₹293 it trades −8.1% versus its 200-day average and sits at 25% of its 52-week range (₹266–₹377).

Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +3% while the NIFTY 500 moved +214% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (12 weeks and counting; last ahead the week of 2026-06-25) — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

Story check

Advanced Enzyme Technologies Ltd's story is not scored yet against the markers our research file set on 22 August 2026. Where it sits in its own cycle: MID_EXPANSION.

What is proven. See the research file

What is not proven yet. Consolidated EBITDA margin remaining below 28% for two consecutive quarters alongside a sustained contraction in Human Healthcare international sales below Rs 500 million per quarter, confirming structural loss of global pricing power rather than transient tariff and energy cost headwinds.

🚨 What would change our mind. Consolidated EBITDA margin remaining below 28% for two consecutive quarters alongside a sustained contraction in Human Healthcare international sales below Rs 500 million per quarter, confirming structural loss of global pricing power rather than transient tariff and energy cost headwinds.

The test written in advance. Consolidated EBITDA margin remaining below 28% for two consecutive quarters alongside a sustained contraction in Human Healthcare international sales below Rs 500 million per quarter, confirming structural loss of global pricing power rather than transient tariff and energy cost headwinds. — the thesis as written as stated by the next result.

Lever 5 · Regulatory approval — BUILDING. EFSA novel-food dossier filed for Serratiopeptidase — approval expected during FY27 (). Upon approval, Advanced Enzymes would hold exclusive EU supply rights for 5-10 years. Product already represents 23% of total revenue (). EU approval adds a new geographic revenue pool to an established commercial base. What proves it keeps working: EU Serratiopeptidase novel-food approval.

Sources: our stock research file (22 August 2026) · quarterly results through Jun 26 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Advanced Enzyme Technologies Ltd reported ₹190 Cr of revenue in the Jun 26 quarter, +2.2% year on year. That is the 7th straight quarter of year-on-year growth. Over 10 years it has compounded at 9.8% a year. The last full year, FY26, came in at ₹746 Cr. The last four reported quarters add to ₹750 Cr.

FY26 revenue came in at ₹746 Cr (+17.1% on the year), capping 10 years at 9.8% compound. The latest quarter (Jun 26) printed ₹190 Cr, +2.2% year on year — the 7th consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +13.1% growth against the decade's 9.8% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +12.3% over the last 4 quarters against +8.9%/yr over the last 8 — accelerating; TTM profit +23.7% vs +10.1%/yr — accelerating.

FY26-Q4. revenue ₹203 Cr and profit ₹45 Cr as reported.

FY27-Q1. revenue ₹190 Cr and profit ₹39 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Advanced Enzyme Technologies Ltd's operating margin is 27.0% in the Jun 26 quarter, −3.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 21.0% to 47.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 27.0%, −3.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 21.0%–47.0%.

🚨 Why the margin moved: operating margin went −3.5 pp year on year while gross margin went +0.7 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

FY26-Q4. revenue ₹203 Cr and profit ₹45 Cr as reported.

FY27-Q1. revenue ₹190 Cr and profit ₹39 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Advanced Enzyme Technologies Ltd earned ₹39.0 Cr of net profit in the Jun 26 quarter, −2.5% year on year. Full-year FY26 profit was ₹174 Cr. The 10-year compound rate is 8.5%. That is 20.5% of the quarter's revenue. The same quarter a year earlier earned ₹40.0 Cr.

Jun 26 profit was ₹39.0 Cr, −2.5% year on year. On the full year, FY26 printed ₹174 Cr (+29.9%), and the 10-year compound rate is 8.5%.

🚨 Why profit moved: revenue contributed +2.2% and the margin −3.0 pp — the quarter was revenue-led despite a thinner margin.

Pace comparison, last four quarters: profit +27.7% vs revenue +13.1%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.

FY26-Q4. revenue ₹203 Cr and profit ₹45 Cr as reported.

FY27-Q1. revenue ₹190 Cr and profit ₹39 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 99% of Advanced Enzyme Technologies Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹157 Cr of operating cash against ₹174 Cr of profit. After ₹82.0 Cr of capital spending, ₹75.0 Cr was left as free cash.

FY26: operating cash of ₹157 Cr against reported profit of ₹174 Cr, leaving free cash of ₹75.0 Cr after ₹82.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 99% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 99%: the cash cycle tightened 22 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.

Router verdict: the bigger cash user is investment — capital spending ran 1.6× depreciation over three years, so the next section's job is to check what that build-out is buying.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Advanced Enzyme Technologies Ltd's cash conversion cycle runs 331 days in FY26, down from 353 days in FY21. Capital spending ran ₹184 Cr over the last 3 years. At FY26 sales of ₹746 Cr each day of that cycle holds about ₹2.0 Cr, so roughly ₹677 Cr sits inside the business at any moment.

Why this happened. Consolidated capex plan includes ₹50 Cr for R&D expansion in FY27 (). Modernized facility triples development bandwidth for 15-20 active pipeline molecules. Confidence capped at 0.40 due to timeline slippages ().

FY26: debtors at 71 days, inventory at 335 days — roughly 11.0 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 331 days, tighter than FY21's 353.

The full loop: cash goes out to suppliers and production on day 0; stock waits 335 days to sell; customers pay about 71 days after that; and suppliers themselves are paid at 76 days — netting out to the 331-day cycle.

In money terms: at FY26 sales of ₹746 Cr, each day of the cycle holds about ₹2.0 Cr — so the 331-day loop keeps roughly ₹677 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹184 Cr over the last 3 fiscal years against ₹112 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹51.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Advanced Enzyme Technologies Ltd earns a ROCE of 14% in FY26. That is up from a trough of 12% in FY14. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 23.3% net margin on 0.41× asset turns.

FY26 ROCE is 14%, recovered from a FY14 trough of 12% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY26): 23.3% net margin × 0.41× asset turns × 1.12× balance-sheet leverage ≈ 10.7% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.

The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 4.0% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.

Advanced Enzyme Technologies Ltd carries ₹32.0 Cr of borrowings against ₹1,632 Cr of equity in FY26, a debt-to-equity of 0.02. Operating profit covers the interest bill 58×. Over 5 years borrowings went from ₹23.0 Cr to ₹32.0 Cr. Capital spending ran ₹184 Cr across the last 3 of those years.

FY26: borrowings of ₹32.0 Cr against equity of ₹1,632 Cr — a debt-to-equity of 0.02. Operating profit covers the interest bill 58×. Over 5 years borrowings went from ₹23.0 Cr to ₹32.0 Cr while capital spending ran ₹184 Cr in just the last 3 — part of the build-out is riding on borrowed money.

The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 4.0% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Foreign institutions added 14.7 points of Advanced Enzyme Technologies Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 26.7% of the company. Domestic institutions moved −3.3 points over the same window, to 4.8%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Foreign institutions: +14.7 points over 8 quarters to 26.7%; Domestic institutions: −3.3 points over 8 quarters to 4.8%; Promoters: +0.2 points over 8 quarters to 43.3%.

Why the register moved: rotation — foreign institutions +14.7 points against domestic institutions −3.3 points over 8 quarters, with promoters holding steady — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Advanced Enzyme Technologies Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Advanced Enzyme Technologies Ltd trades at 20.8× P/E, near the bottom of its own range — cheaper only 20% of the time. Its long-run median P/E is 27.7×, measured across 10.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 20.8× is near the bottom of its own range — cheaper only 20% of the time, against a long-run median of 27.7× measured over 10.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved +28.6% against a −13.4% price move — earnings outran the price, pushing the multiple DOWN its own range.

The price move, decomposed: over 5y, of the −4.4%/yr price move, ~+1.1%/yr came from earnings growth and ~−5.5 pp from the multiple (compressing); over 10y, of the +0.3%/yr price move, ~+5.7%/yr came from earnings growth and ~−5.4 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.

The PEG ratio and its quarterly curve, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 4.0% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.

Solved at its 26 August 2026 price, Advanced Enzyme Technologies Ltd was paying for profit growth of about 12.1% a year. Profit itself has compounded 8.5% a year over the past 10 years. Today the market pays 20.8× P/E, the 20th percentile of its own 10-year range.

What the two numbers say together. The multiple is low against its own past, and the growth the price is paying for is close to what this company has actually delivered.

How to hold this number: it is a reading of one day's price, taken on 26 August 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.

Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Advanced Enzyme Technologies Ltd reads as turning around on its fundamental arc. Turning around — profit growth swung from −1.5% at the trough to +23.7% off a 4-quarter-old trough, ROCE holding at 14.0%. The read is built from 8 quarters across 4 curves, on partial evidence.

Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.

4-Factor Sector Score

54.4/100 — rank 1 of 3 in Seeds/Tissue Culture/Bio Technology · 79% evidence confidence

Advanced Enzyme Technologies Ltd scores 54.4 out of 100 against the 3 companies it is compared with in Seeds/Tissue Culture/Bio Technology, ranking 1. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 19.5 + 15.5 + 12.1 + 7.3 = 54.4. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Said versus delivered

What Advanced Enzyme Technologies Ltd's management promised, set against what actually arrived — 4 tracked promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.

Intermediates Initiative Abandoned · 12 August 2026. The latest call reverses the February 2026 position that management was still pursuing the intermediates opportunity and expected to establish a foothold. This is a strategic change in a segment management still described as high-growth, but the latest call does not explain why the initiative was abandoned.

🚨 Nashik R&D Center Timeline Slippage · 12 May 2026. Both the Nov 2025 and Feb 2026 calls committed to full commissioning of the Nashik R&D center by end of Q2 FY27 (September 2026), with the Nov 2025 call additionally promising partial activation by March 2026. The May 2026 call makes no mention of partial operations having started and now only guides full operationalization to the latter half of FY27, an unexplained delay past the September 2026 milestone stated explicitly across both prior calls.

US Business Outlook Reversal · 12 May 2026. In the Feb 2026 call, management expressed explicit optimism about US recovery, stating increased inquiries and interest would reflect positively in FY26 performance itself. The May 2026 call, however, reports US Q4 FY26 revenue down 11% year-on-year and characterizes FY27 as a very challenging year with no clear explanation of what deteriorated in the roughly three months between the two calls.

🚨 R&D Center Commissioning Delay · 4 February 2026. In the November 2025 call, management guided that the new R&D center would likely be capitalized and partially active by the end of the fiscal year (March 2026). However, in the February 2026 call, the timeline was pushed back significantly to the end of the second quarter of the coming year (approx. September 2026) without elaborating on the cause of the delay. Earlier call (Nov 2025): “Probably, by the end of the March, it should have some kind of shape... It will partially become active by the end of this fiscal year.” Later call (Feb 2026): “Commissioning should be around the end of the second quarter of the coming year.”

Every quote above is taken word for word from the company’s own earnings calls.

Frequently asked questions